Hematological malignancy
Conditions
Interventions
experimental group:HLA mismatched allo-HSCT
Sponsors
The First Affiliated Hospital of Medical College of Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients with high-risk hematological malignancies (18-55 years old) had allo HSCT indications; 2. Unrelated HLA identical sibling donors; 3. There are no unrelated donors with HLA matching >= 8 / 10, or it is difficult to find non blood donors because of the emergency condition; 4. There is no suitable donor for HLA matching; 5. There is no suitable umbilical cord blood donor; 6. Suitable donors with mismatched HLA matching (within three generations and HLA high resolution matching < 5 / 10); 7. Subjects or their legal representatives sign informed consent before the start of clinical study.
Exclusion criteria
Exclusion criteria: 1. Patients with severe liver and kidney function (alanine aminotransferase > 2.5 times of the upper normal limit, serum creatinine > 1.5 times of the upper normal limit), and patients with cardiopulmonary insufficiency (NYHA III / IV, cardiac ejection fraction = 2; 4. Patients with secondary tumor; 5. Patients with severe central nervous system disease or mental illness can not choose to enter or withdraw from clinical trials; 6. Patients with other contraindications of allo HSCT.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| neutrophil engraftment;platelet engraftment;incidence of GVHD; | — |
Secondary
| Measure | Time frame |
|---|---|
| Immune reconstitution;incidence of infection;overall survival;disease-free survival;cumulative replase rate;nonreplase mortality; | — |
Countries
China
Contacts
Public ContactHe Huang
The First Affiliated Hospital of Medical College of Zhejiang University
Outcome results
None listed